211 related articles for article (PubMed ID: 17115121)
21. [Pelizaeus-Merzbacher disease(PMD)/spastic paraplegia 2(SPG2)].
Eto Y
Ryoikibetsu Shokogun Shirizu; 2000; (29 Pt 4):536-7. PubMed ID: 11032015
[No Abstract] [Full Text] [Related]
22. Myelin-associated glycoprotein gene mutation causes Pelizaeus-Merzbacher disease-like disorder.
Lossos A; Elazar N; Lerer I; Schueler-Furman O; Fellig Y; Glick B; Zimmerman BE; Azulay H; Dotan S; Goldberg S; Gomori JM; Ponger P; Newman JP; Marreed H; Steck AJ; Schaeren-Wiemers N; Mor N; Harel M; Geiger T; Eshed-Eisenbach Y; Meiner V; Peles E
Brain; 2015 Sep; 138(Pt 9):2521-36. PubMed ID: 26179919
[TBL] [Abstract][Full Text] [Related]
23. PLP overexpression perturbs myelin protein composition and myelination in a mouse model of Pelizaeus-Merzbacher disease.
Karim SA; Barrie JA; McCulloch MC; Montague P; Edgar JM; Kirkham D; Anderson TJ; Nave KA; Griffiths IR; McLaughlin M
Glia; 2007 Mar; 55(4):341-51. PubMed ID: 17133418
[TBL] [Abstract][Full Text] [Related]
24. Clinically relevant intronic splicing enhancer mutation in myelin proteolipid protein leads to progressive microglia and astrocyte activation in white and gray matter regions of the brain.
Bachstetter AD; Webster SJ; Van Eldik LJ; Cambi F
J Neuroinflammation; 2013 Dec; 10():146. PubMed ID: 24314267
[TBL] [Abstract][Full Text] [Related]
25. PLP1 gene duplication causes overexpression and alteration of the PLP/DM20 splicing balance in fibroblasts from Pelizaeus-Merzbacher disease patients.
Regis S; Grossi S; Corsolini F; Biancheri R; Filocamo M
Biochim Biophys Acta; 2009 Jun; 1792(6):548-54. PubMed ID: 19376225
[TBL] [Abstract][Full Text] [Related]
26. Pelizaeus-Merzbacher disease.
Koeppen AH; Robitaille Y
J Neuropathol Exp Neurol; 2002 Sep; 61(9):747-59. PubMed ID: 12230321
[TBL] [Abstract][Full Text] [Related]
27. A new polymorphism in the proteolipid protein (PLP1) gene and its use for carrier detection of PLP1 gene duplication in Pelizaeus-Merzbacher disease.
Hobson G; Stabley D; Funanage V; Marks H
Hum Mutat; 2001 Feb; 17(2):152. PubMed ID: 11180600
[TBL] [Abstract][Full Text] [Related]
28. CNS myelination and PLP gene dosage.
Woodward K; Malcolm S
Pharmacogenomics; 2001 Aug; 2(3):263-72. PubMed ID: 11535114
[TBL] [Abstract][Full Text] [Related]
29. A brief history of Pelizaeus-Merzbacher disease and proteolipid protein.
Koeppen AH
J Neurol Sci; 2005 Feb; 228(2):198-200. PubMed ID: 15694205
[No Abstract] [Full Text] [Related]
30. Gait abnormalities and progressive myelin degeneration in a new murine model of Pelizaeus-Merzbacher disease with tandem genomic duplication.
Clark K; Sakowski L; Sperle K; Banser L; Landel CP; Bessert DA; Skoff RP; Hobson GM
J Neurosci; 2013 Jul; 33(29):11788-99. PubMed ID: 23864668
[TBL] [Abstract][Full Text] [Related]
31. A novel PLP1 mutation associated with optic nerve enlargement in two siblings with Pelizaeus-Merzbacher disease: A new MRI finding.
Pavlidou E; Ramachandran V; Govender V; Wilson C; Das R; Vlachou V; Pavlou E; Saggar A; Mankad K; Kinali M
Brain Dev; 2017 Mar; 39(3):271-274. PubMed ID: 27793435
[TBL] [Abstract][Full Text] [Related]
32. A novel proteolipid protein 1 gene mutation causing classical type Pelizaeus-Merzbacher disease.
Fukumura S; Adachi N; Nagao M; Tsutsumi H
Brain Dev; 2011 Sep; 33(8):697-9. PubMed ID: 21177054
[TBL] [Abstract][Full Text] [Related]
33. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation.
Garbern JY; Yool DA; Moore GJ; Wilds IB; Faulk MW; Klugmann M; Nave KA; Sistermans EA; van der Knaap MS; Bird TD; Shy ME; Kamholz JA; Griffiths IR
Brain; 2002 Mar; 125(Pt 3):551-61. PubMed ID: 11872612
[TBL] [Abstract][Full Text] [Related]
34. Genotype-phenotype correlation in inherited brain myelination defects due to proteolipid protein gene mutations. Clinical European Network on Brain Dysmyelinating Disease.
Cailloux F; Gauthier-Barichard F; Mimault C; Isabelle V; Courtois V; Giraud G; Dastugue B; Boespflug-Tanguy O
Eur J Hum Genet; 2000 Nov; 8(11):837-45. PubMed ID: 11093273
[TBL] [Abstract][Full Text] [Related]
35. Modeling the natural history of Pelizaeus-Merzbacher disease.
Mayer JA; Griffiths IR; Goldman JE; Smith CM; Cooksey E; Radcliff AB; Duncan ID
Neurobiol Dis; 2015 Mar; 75():115-30. PubMed ID: 25562656
[TBL] [Abstract][Full Text] [Related]
36. Aberrant trafficking of a proteolipid protein in a mild Pelizaeus-Merzbacher disease.
Koizume S; Takizawa S; Fujita K; Aida N; Yamashita S; Miyagi Y; Osaka H
Neuroscience; 2006 Sep; 141(4):1861-9. PubMed ID: 16844304
[TBL] [Abstract][Full Text] [Related]
37. Deletion of a splicing enhancer disrupts PLP1/DM20 ratio and myelin stability.
Wang E; Dimova N; Sperle K; Huang Z; Lock L; McCulloch MC; Edgar JM; Hobson GM; Cambi F
Exp Neurol; 2008 Dec; 214(2):322-30. PubMed ID: 18835559
[TBL] [Abstract][Full Text] [Related]
38. Neural stem cells restore myelin in a demyelinating model of Pelizaeus-Merzbacher disease.
Gruenenfelder FI; McLaughlin M; Griffiths IR; Garbern J; Thomson G; Kuzman P; Barrie JA; McCulloch ML; Penderis J; Stassart R; Nave KA; Edgar JM
Brain; 2020 May; 143(5):1383-1399. PubMed ID: 32419025
[TBL] [Abstract][Full Text] [Related]
39. Three new PLP1 splicing mutations demonstrate pathogenic and phenotypic diversity of Pelizaeus-Merzbacher disease.
Laššuthová P; Žaliová M; Inoue K; Haberlová J; Sixtová K; Sakmaryová I; Paděrová K; Mazanec R; Zámečník J; Šišková D; Garbern J; Seeman P
J Child Neurol; 2014 Jul; 29(7):924-31. PubMed ID: 23771846
[TBL] [Abstract][Full Text] [Related]
40. PLP/DM20 expression and turnover in a transgenic mouse model of Pelizaeus-Merzbacher disease.
Karim SA; Barrie JA; McCulloch MC; Montague P; Edgar JM; Iden DL; Anderson TJ; Nave KA; Griffiths IR; McLaughlin M
Glia; 2010 Nov; 58(14):1727-38. PubMed ID: 20629189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
